Report Details:
15 Companies Covered
138 Pages
Market Research Future (MRFR) has updated the report that the global Veterinary Medicine Market, valuing the market at USD 46.48 billion in 2025 and projecting it to grow to USD 49.96 billion in 2026, reaching USD 95.63 billion by 2035 at a compound annual growth rate (CAGR) of 7.48% during the forecast period 2026--2035.
The market is being transformed by rising global expenditure on animal disease treatment, one-health policy alignment, and antibiotic stewardship regulations such as the FDA's Guidance for Industry #263 and the EU Veterinary Medicinal Products Regulation 2019/6, which are accelerating demand for vaccines, biologics, and next-generation parasiticides.
Market Overview
Veterinary care is now strategically essential for animal health. systems worldwide are changing as businesses want to provide better care results for both livestock and pets. The convergence of pets Antimicrobial resistance regulations, humanization tendencies, and recombinant Innovation in vaccine platforms is radically changing how veterinarians oversee the treatment of animal illnesses, fostering a healthy growing environment for global providers of biologics and pharmaceuticals.
North America commands approximately 38.1% of the global market share, anchored by the United States' USD 36 billion companion-animal care economy. Europe holds around 27.0% of global share, while Asia-Pacific is recognized as the fastest-growing region, with a CAGR of 10.80%, propelled by surging pet adoption in China and India and industrialized livestock veterinary care across Southeast Asia.
Key Market Trends & Growth Drivers
- Rising Pet Ownership and Humanization: 67% of U.S. households---approximately 87 million homes---owned a pet in 2024, up from 56% a decade earlier. This structural shift is translating pet health medications from a discretionary spend into a recurring healthcare obligation, with average annual per-pet pharmaceutical expenditure surpassing USD 400 in the United States. China's urban pet population exceeded 120 million in 2024, creating an addressable companion animal pharmaceuticals pool worth over USD 5.2 billion.
- Antibiotic Stewardship and Regulatory Mandates: The EU's Regulation 2019/6 and the FDA's five-year antimicrobial resistance action plan have collectively removed over 70 previously approved antibiotic feed- grade indications since 2022, redirecting demand toward vaccines and The Veterinary Medicine Market benefits directly as producers substitute growth-promoting antibiotics with licensed immunological alternatives.
- Biologics and Recombinant Vaccine Platforms: Legacy small-molecule generics are ceding ground to recombinant platforms, monoclonal antibody therapies, and gene-edited vaccines. Venture capital deployed into companion animal pharmaceuticals exceeded USD 2.8 billion globally in 2024, reflecting investor conviction that biologics---which carry gross margins of 40--60% versus 20--30% for generics---will anchor the next innovation cycle.
- E-Pharmacy and Telehealth Channel Expansion: E-pharmacy channels, still at roughly 13% penetration, are widening owner access to chronic- care prescriptions for pet health medications and reducing dispensing Veterinary telehealth consultations grew 280% between 2020 and 2024, pairing remote consultations with e-pharmacy fulfillment to expand geographic access in underserved rural corridors.
- One-Health Policy Convergence: The intersection of human, animal, and environmental health---formalized through WHO's One Health Joint Plan of Action---is directing over USD 3.4 billion in multilateral funding toward zoonotic surveillance, antimicrobial resistance monitoring, and cross-species vaccine development through 2030. This convergence positions livestock veterinary care as a public-health investment, not merely an agricultural input.
Market Segmentation Insights
By Product Type: Drugs hold the largest share, capturing approximately 52.5% of the market in 2025, supported by broad-spectrum anti-infectives and parasiticides. Vaccines are the fastest-growing product segment at a 9.70% CAGR, driven by recombinant and mRNA platform adoption. Medicated feed additives contributed USD 7.88 billion in 2025, serving antibiotic-alternative supplementation demand.
By Animal Type: Companion animals lead with the largest share at 51.5% in 2025, reflecting the premiumization of pet health medications and rising pet insurance penetration. Livestock treatments are the fastest-growing animal segment at an 11.24% CAGR, led by poultry and swine biologics as industrialized operations formalize livestock veterinary care standards.
By Mode of Delivery: Parenteral delivery dominates with approximately 44.0% share in 2025, as vaccines, biologics, and many livestock antibiotics require injection for efficacy. Topical formulations are the fastest-growing delivery mode at a 9.16% CAGR, driven by consumer-friendly spot-on and collar-based delivery of pet health medications.
By End User: Veterinary hospitals hold the largest share at approximately 53.5% in 2025, through bundled diagnostic and treatment services integrating advanced animal clinical diagnosis with immediate dispensing. Veterinary clinics represent the fastest-growing end-user segment at a 11.65% CAGR, as telehealth platforms route chronic-care and refill prescriptions to lower-overhead settings.
Regional Landscape
North America -- Companion Animal Care Economy Leader
North America dominates the Veterinary Medicine Market, commanding approximately 38.1% of global market share. Growth in the region is anchored by the United States' USD 36+ billion companion-animal care economy, where pet insurance penetration---now above 4.6%---is lowering out-of-pocket friction for premium pet health medications. Canada's Veterinary Drug Directorate has tightened antimicrobial oversight, accelerating vaccine adoption for livestock veterinary care across dairy and beef operations. Mexico's poultry and cattle vaccination programs contribute to regional growth.
Europe -- Antimicrobial Reduction and Farm to Fork Strategy
Europe accounts for around 27.0% of the global market, shaped by the EU's Farm to Fork strategy targeting a 50% reduction in antimicrobial sales for food-producing animals by 2030. This regulatory pressure is the single largest catalyst converting antibiotic prescriptions to vaccine-based animal disease treatment regimens across the continent. Germany leads regional adoption with advanced diagnostics and companion animal spending, followed by the UK, France, Italy, and Spain. The Nordic nations drive digital veterinary platform adoption.
Asia-Pacific -- Fastest-Growing Animal Health Frontier
Asia-Pacific is the fastest-growing region with a 10.80% CAGR, propelled by surging pet adoption and industrialized livestock veterinary care. China's pet population surpassed 120 million in 2024, generating a companion animal pharmaceuticals segment growing above 14% annually. India's National Livestock Mission allocates over USD 800 million toward animal health infrastructure, directly expanding livestock veterinary care access across smallholder dairy and poultry operations. Japan and South Korea drive regional innovation through premium companion animal pharmaceuticals and pet humanization trends.
Middle East and Africa -- Poultry Self-Sufficiency and Zoonotic Preparedness
The Middle East and Africa region holds an emerging share of the global market, with growth driven by Saudi Arabia's National Transformation Program targeting 80% poultry self-sufficiency by 2030, channeling investment into hatchery-level vaccination infrastructure and biosecurity-grade animal disease treatment protocols. The UAE's premium pet care urbanization and South Africa's livestock disease management programs contribute to regional development. Egypt's poultry vaccination scale-up and zoonotic disease preparedness funding across Sub-Saharan Africa accelerate regional adoption.
Competitive Landscape
The Veterinary Medicine Market exhibits moderate concentration, with the top four companies collectively holding an estimated 55--60% of global revenue. The Herfindahl-Hirschman Index sits between 1,200 and 1,500, indicating a moderately consolidated structure where scale advantages in R&D, regulatory dossier breadth, and multispecies portfolios create durable competitive moats. Major players include Zoetis Inc., Boehringer Ingelheim, Merck Animal Health, Elanco Animal Health, IDEXX Laboratories, Virbac, Dechra Pharmaceuticals, Vetoquinol SA, Phibro Animal Health, and Ceva Santé Animale. Key recent developments include:
- Zoetis received a USDA conditional license in October 2024 for a novel mRNA vaccine targeting avian influenza in commercial poultry, marking the first mRNA veterinary vaccine approval in North America.
- Boehringer Ingelheim completed a USD 1.2 billion expansion of its biologics manufacturing facility in Lyon, France in July 2024, doubling vaccine production capacity for poultry and swine.
- Elanco launched Credelio Quattro in March 2024, a combination parasiticide covering heartworm, fleas, ticks, and intestinal worms in a single monthly chewable dose for companion animal pharmaceuticals.
- The European Medicines Agency published updated guidelines in January 2024 reducing maximum antibiotic treatment durations for food-producing animals across the EU, accelerating vaccine substitution in livestock veterinary care.
- Ceva Santé Animale opened a USD 350 million vaccine production campusin Suzhou, China in November 2023, targeting Asia-Pacific poultry and swine biologics demand.
Future Outlook
Further developments in mRNA and gene-edited vaccination platforms, increased telehealth-enabled prescription routing, and increased penetration into emerging markets in Asia-Pacific, the Middle East, and Africa are predicted to transform the veterinary medicine business by 2035. Businesses that put a high priority on developing biologics pipelines, integrated diagnostic-to-prescription ecosystems, and ESG-driven supply chains that are sustainable are well-positioned to benefit from disproportionate growth.
The integration of AI-driven analytics for improved animal clinical diagnosis insights, the creation of unified e-pharmacy and subscription fulfillment models, and the expansion of customized products in high-growth emerging markets through government-funded livestock modernization and national insurance coverage expansion are among the major growth opportunities noted in the MRFR report.
